Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Michael Hallek and Clemens-Martin Wendtner.
Michael Hallek
Connection Strength
1.250
Clemens-Martin Wendtner
  1. CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019 05; 33(5):1161-1172.
    View in: PubMed
    Score: 0.200
  2. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 09; 19(9):1215-1228.
    View in: PubMed
    Score: 0.195
  3. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018 Mar; 14(6):499-513.
    View in: PubMed
    Score: 0.189
  4. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct; 4(10):e475-e486.
    View in: PubMed
    Score: 0.183
  5. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14; 127(2):208-15.
    View in: PubMed
    Score: 0.161
  6. Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma. 2008 Dec; 49(12):2256-62.
    View in: PubMed
    Score: 0.100
  7. COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia. 2020 08; 34(8):2225-2229.
    View in: PubMed
    Score: 0.056
  8. Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Br J Haematol. 2018 12; 183(5):727-735.
    View in: PubMed
    Score: 0.050
  9. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 07 01; 36(19):1973-1980.
    View in: PubMed
    Score: 0.048
  10. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018 02 20; 9(1):727.
    View in: PubMed
    Score: 0.047
  11. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol. 2007 Jan; 136(1):63-72.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.